EcoDrugPlus

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSCCRG00000041042
Gene Symbol: HTR1B
1 Cross references
177 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSCCRG00000049481
Gene Symbol: HTR1B
1 Cross references
177 Possible Orthologues:

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSCCRG00000033056
Gene Symbol: HTR1E
1 Cross references
144 Possible Orthologues:

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSCCRG00000075833
Gene Symbol: HTR1E
1 Cross references
144 Possible Orthologues:

5-Hydroxytryptamine Receptor 1f

Ensembl ID : ENSCCRG00000081290
Gene Symbol: HTR1F
1 Cross references
139 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSCCRG00000045888
Gene Symbol: HTR2A
1 Cross references
201 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSCCRG00000058961
Gene Symbol: HTR2A
1 Cross references
200 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSCCRG00000048728
Gene Symbol: HTR2A
1 Cross references
202 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSCCRG00000069530
Gene Symbol: HTR3A
1 Cross references
202 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSCCRG00000081399
Gene Symbol: HTR3A
1 Cross references
202 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSCCRG00000017340
Gene Symbol: HTR3B
1 Cross references
171 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSCCRG00000050507
Gene Symbol: HTR3B
1 Cross references
172 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).